targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00506155 | Completed | 2 | 2007-06-01 | null | null | null | null | Phase II+ | 1,571,958,031,733 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028756 | Completed | 3 | 2001-10-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003376 | Completed | 3 | 1998-09-01 | null | null | null | Phase III+ | Phase II+ | 1,640,677,508,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003103 | Completed | 1 | 1997-08-01 | null | null | null | null | null | 1,666,447,311,151 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022633 | Terminated | 2 | 2001-07-01 | Terminated | stopped | null | null | Phase II+ | 1,675,037,246,695 | Permanently Closed Due to Poor Accrual | Phase 2 | 31/07/2001 | Terminated | 11/08/2016 | 31/07/2011 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00004223 | Completed | 2 | 1999-12-01 | null | null | null | null | Phase II+ | 1,683,627,181,300 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000261456 | Orphanet_59305 | NCT02639650 | Unknown status | 3 | 2016-03-01 | null | null | null | Phase III+ | Phase II+ | 670,014,899,450 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in single | Tissue enhanced | none | chembl | known_drug | 413,311 |
ENSG00000268089 | MONDO_0024355 | NCT00611195 | Completed | 4 | 2008-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 704,374,636,712 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005741 | infectious disease | Other | null | null | Detected in some | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000269858 | EFO_0008585 | NCT04803864 | Recruiting | 2 | 2021-06-10 | null | null | null | null | Phase II+ | 661,424,963,945 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 1 | null | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000269858 | EFO_0008585 | NCT04803864 | Recruiting | 2 | 2021-06-10 | null | null | null | null | Phase II+ | 661,424,963,945 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | null | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000269858 | EFO_0008585 | NCT04803864 | Recruiting | 2 | 2021-06-10 | null | null | null | null | Phase II+ | 661,424,963,945 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | null | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000274286 | EFO_0009085 | NCT01785693 | Completed | 4 | 2013-01-30 | null | null | Phase IV | Phase III+ | Phase II+ | 1,374,389,535,088 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | null | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT01646684 | Completed | 1 | 2013-03-08 | null | null | null | null | null | 1,168,231,105,229 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT01646684 | Completed | 1 | 2013-03-08 | null | null | null | null | null | 1,168,231,105,229 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT01313559 | Terminated | 2 | 2011-06-01 | Terminated | stopped | null | null | Phase II+ | 154,618,824,322 | Slow accrual | Phase 2 | 30/06/2011 | Terminated | 25/04/2018 | 29/11/2012 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT01313559 | Terminated | 2 | 2011-06-01 | Terminated | stopped | null | null | Phase II+ | 154,618,824,322 | Slow accrual | Phase 2 | 30/06/2011 | Terminated | 25/04/2018 | 29/11/2012 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT00510224 | Terminated | 2 | 2007-07-01 | Terminated | stopped | null | null | Phase II+ | 300,647,711,166 | Stopped at interim analyses phase due to lack of efficacy | Phase 2 | 31/07/2007 | Terminated | 11/12/2013 | 31/08/2009 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT00510224 | Terminated | 2 | 2007-07-01 | Terminated | stopped | null | null | Phase II+ | 300,647,711,166 | Stopped at interim analyses phase due to lack of efficacy | Phase 2 | 31/07/2007 | Terminated | 11/12/2013 | 31/08/2009 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT00166725 | Completed | 2 | 2004-02-01 | null | null | null | null | Phase II+ | 867,583,394,385 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000278195 | MONDO_0008315 | NCT00166725 | Completed | 2 | 2004-02-01 | null | null | null | null | Phase II+ | 867,583,394,385 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000278195 | MONDO_0015277 | NCT01625520 | Completed | 2 | 2012-02-01 | null | null | null | null | Phase II+ | 755,914,244,980 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in some | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |